An at-home highly sensitive PCR based COVID diagnostic test
Flexbiotech Inc, Tempe, Arizona, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Our solution is a highly sensitive, handheld, semi-disposable at-home Point-of-Need diagnostic reader using the gold-standard PCR method to deliver results in less than 30 minutes. It requires a salivary sample and costs less than $10 per test in the US with previously proven technology for cancer.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: FlexBioTech has a corporate mission of extending the benefits of medical diagnostics to the underserved. We intend to be a sustainable business. The mission and intent do align with investment from philanthropic organizations and alike. The company’s discussions with those organizations indicate that they require innovation and that they are interested in the innovations of FlexBioTech’s diagnostic solutions. Specifically, low cost, ease of use, small form factor, and ruggedness improve the philanthropic organizations’ ability to achieve their missions which typically focus on low- and lower-middle-income countries. The commercial organizations that would benefit from FlexBioTech’s device are electronics equipment manufacturers and companies that make linear flow assay cartridges. In general, FlexBioTech simply offers an increased market size to those commercial organizations that manufacture devices to FDA & ISO standards. FlexBioTech has designed its device to take advantage of existing manufacturing facilities and installed equipment. Since this is an advanced technology, many of those facilities have only recently been brought online and may be operating at less than full capacity. Several such companies have expressed interest in completing FlexBioTech’s design in a manner that utilizes their factory’s capabilities.